• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

Novartis AG (NYSE: NVS)

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *

 

	Start	1996-12-20 merged
	Group	Novartis (Group)
	Industry	LIFE SCIENCES
	Person	Jimenez, Joseph (Novartis 201002–CEO before since 200704 CEO Consumer Health)
	Person 2	Kirsch, Harry (Novartis 201304– Group CFO before CFO of Novartis Pharmaceuticals)
	Region	Basel BS
	Country	Switzerland
	City	4002 Basel BS
	Tel	41 61 324 8000
		Address record changed: 2018-07-24
Basic data	Employees	J: more than 100,0 (2017-12-31)
	Currency	USD
	Annual sales	49,109,000,000 (sales, net, consolidated (2017) 2017-12-31)
	Profit	7,703,000,000 (2017-12-31)
	Cash	9,485,000 (2017-12-31)
		* Document for �About Section�: Novartis AG. (1/27/16). "Press Release: Novartis Delivered Strong Sales Growth and Core Margin Expansion (cc[1]) in 2015, Announces Plans to Accelerate Growth at Alcon, Streamline Group Operations". Basel.
		Record changed: 2019-07-23

Advertisement

More documents for Novartis (Group)

• [1] iTeos Therapeutics S.A.. (8/13/19). "Press Release: iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer". Gosselies & Cambridge, MA....
• [2] Pharming Group N.V.. (8/13/19). "Press Release: Pharming Acquires Exclusive License to CDZ173, a Late Stage Drug for the Treatment of APDS". Leiden....
• [3] Novartis AG. (7/19/19). "Press Release: Novartis Key Multiple Sclerosis Product Gilenya Approved in China". Basel....
• [4] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
• [5] Novartis AG. (7/16/19). "Press Release: FDA Accepts File and Accelerates Review of Novartis Sickle Cell Disease Medicine Crizanlizumab (SEG101)". Basel....
• [6] Novartis AG. (7/11/19). "Press Release: Novartis, Amgen and Banner Alzheimer's Institute Discontinue Clinical Program with BACE inhibitor CNP520 for Alzheimer's Prevention". Basel....
• [7] Sanofi S.A.. (6/7/19). "Press Release: Paul Hudson to Succeed Olivier Brandicourt as Chief Executive Officer". Paris....
• [8] Novartis AG. (4/24/19). "Press Release: Novartis Starts 2019 with Strong Sales and Double Digit Core Operating Income Growth, Mayzent Launch and Alcon Spin-off, Profit Guidance Upgraded". Basel....
• [9] Poseida Therapeutics, Inc.. (4/22/19). "Press Release: Poseida Therapeutics Raises $142 Million in Series C Financing". San Diego, CA....
• [10] Novartis AG. (4/4/19). "Press Release: Novartis Updates on the Migraine Collaboration with Amgen". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.